Standard Biotools (LAB) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Standard Biotools (LAB) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 132.13 Bn | 129.26 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 111.43 Bn | 102.21 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 68.97 Bn | 67.52 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.64 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.91 Bn | 27.79 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 28.86 Bn | 26.58 Bn | 1.98 Bn | -30.10% |
| 8 | Smith & Nephew | 28.12 Bn | 27.54 Bn | - | - |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn | 98.68% |
| 10 | Standard Biotools | 302.22 Mn | -152.96 Mn | 11.31 Mn | 5,420.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,420.84% |
| Dec 31, 2025 | -115.63% |
| Sep 30, 2025 | -58.25% |
| Jun 30, 2025 | 30.54% |
| Mar 31, 2025 | 91.71% |
| Dec 31, 2024 | -1.78% |
| Sep 30, 2024 | -4.14% |
| Jun 30, 2024 | -49.33% |
| Mar 31, 2024 | -90.76% |
| Dec 31, 2023 | -90.78% |
| Sep 30, 2023 | 28.47% |
| Jun 30, 2023 | 73.19% |
| Mar 31, 2023 | 77.92% |
| Sep 30, 2022 | 40.93% |
| Jun 30, 2022 | -76.77% |
| Mar 31, 2022 | -305.96% |
| Sep 30, 2021 | -724.51% |
| Jun 30, 2021 | -176.24% |
| Mar 31, 2021 | -17.74% |
| Dec 31, 2020 | -42.36% |